Gaming-, Koch- und Gewichtheben-Enthusiast. 🎮💪
Munich
Joined March 2023
- Tweets5.1K
- Following299
- Followers262
- Likes8.8K
Congratulations on the editorial. This mirrors what we often see in immunology: tumor behavior tells us more than any single marker. Biology-guided, function-preserving management is the right direction for BMF-pRCC.
📢 New editorial out in @EurUrolOncol!
Rethinking the 3-cm rule in #RCC: is size enough?
Long-term evidence in sporadic bilateral multifocal pRCC suggests that when we intervene may be as important as how.
Great pleasure to work with @Selcuk__Erdem & @u_capitanio
Philipp Doc retweeted
For readers interested in individualized (n-of-1) therapies, here's a comprehensive review including a roadmap for their development
nature.com/articles/s41573-0…
rdcu.be/1DCEZDkduGca
Philipp Doc retweeted
Drs Andrew Trinh and Sophia Ling are fantastic gastroenterology colleagues @PeterMacCC
Thanks so much for helping @NzsOncology put together this free irAE webinar series 🤩 great resource!
@MOGA_ORG @ONCOassist @OncoAlert @ASPIRE_CoP @IndianYoungOnco @oncodaily
The latest of our #NZSOimmunotoxwebinar series is now available online as a FREE resource for any to use and reference! Share widely amongst colleagues 👉nzsoncology.org.nz/webinarse…
Philipp Doc retweeted
Delays and denials have become an infamous feature of the American healthcare system. In Texas, one widow wonders if an “insurance issue” contributed to her husband’s suicide. @laurenmsausser reports ⤵️
kffhealthnews.org/health-ind…
Philipp Doc retweeted
🚨 #FDAApproval: The @FDA has granted approval for pirtobrutinib (Jaypirca) for adults with previously untreated #CLL or #SLL without a known 17p deletion.
Approval was supported by BRUIN CLL-313 trial findings.
🔗 ascopost.com/news/october-20…
Philipp Doc retweeted
Review über für Frauen spezifische Mechanismen bei chronischen Schmerzen, das die ganze Sache ins Jahr 2026 befördert.
"Women are desperately waiting for concrete answers that might help eliminate the common "all in your head" approach to their illnesses."
It has long been recognized that millions of women, especially younger women, are disproportionately affected by pain disorders.
In a new #ScienceReview, researchers synthesize recent advances in understanding these conditions. scim.ag/3VcRS4H
Philipp Doc retweeted
🧬 Cracking the Code of Life with AI
Our Founder & Co-CEO, Alex Zhavoronkov, PhD, is heading to the Abundance Longevity Trip in #SanFrancisco to talk about using frontier AI to develop longevity therapeutics.
Alex has been invited to attend the Abundance Longevity Trip, founded by Dr. Peter H. Diamandis.
As a recognized thought leader in #aging research and #longevity biotechnology, Dr. Zhavoronkov will join top global longevity scientists and biotech founders. Drawing from Insilico's pioneering breakthroughs, he will share insights into AI biology of aging, anti-aging interventions, and longevity drug discovery, joining fellow delegates to usher in a new era of AI-driven longevity medicine.
If you're there, don't miss this session! For more information, please visit: longevity.abundance360.com/?…
Good editorial. The bottleneck in gastric cancer is no longer drug development but biomarker-driven sequencing. In my experience HER2, PD-L1 CPS and MSI status all change the optimal first move, and that guidance is still maturing.
New editorial by @VaiaFlorou and Dr. Lindsay Hannan on how new treatments are improving outcomes for patients with gastric cancer. Determining how to best select, combine, and sequence these therapies remains a clinical challenge.
🔗: acsjournals.onlinelibrary.wi…
@OncoAlert
Philipp Doc retweeted
#BreastCancerAwarenessMonth begins today🎗️ All month long, we will be sharing education and resources, highlighting our testing solutions, and more.
#BreastCancerAwarenessMonth #BreastCancerAwareness2025 #CancerTesting #Oncology #NeoGenomics
This kind of unrest is why professionals in my field think hard about where their work and families are secure. Stable governance and functioning institutions matter more than ever.
Multicultural France is a hell on earth.
Readers added context they thought people might want to know
La vidéo montre l'incendie accidentel d'un bus scolaire en 2023
tf1info.fr/justice-faits-…
Philipp Doc retweeted
Autologous serum trial shown in large trial to truly benefit #Sjogrens dry eyes at the Paris International Sjogrens Symposium
I read the figure: no current evidence of durable NED, outcomes self-reported at 6 months, no control group. Presenting 84.4% as remission data misreads the study badly. This is hypothesis-generating at best, nothing more.
Philipp Doc retweeted
We have 3 Anti-Her2 options today for Upper GI adenocarcinoma. Here is the table outlining dose, common toxicities, and clinical pearls in managing these AEs that we touched on during our #ToxCheck discussion with @ShrutiPatelMD & @Sam_Cytryn
#MedTwitter #MedX #OncTwitter
Tox-Check: Anti-Her2 drugs in Upper GI (Esophageal, GE Junction, and Gastric Adenocarcinoma) w/ @ShrutiPatelMD & @Sam_Cytryn
✅ Trastuzumab
✅ Zanidatamab
✅ TDXd
Full 🗣️:
⭐️ oncbrothers.com/toxcheck-her…
⭐️ “Oncology Brothers” podcast
#OncTwitter @OncoAlert @OncUpdates #gism
Philipp Doc retweeted
Insilico Medicine nominates ISM1354, an AI-driven small-molecule GIPR antagonist, as a preclinical candidate for obesity.
🧬 Preclinical findings support its advancement into further safety studies. 🔬 #AIDrugDiscovery #DrugDevelopment
Im Klinikalltag treffe ich täglich Entscheidungen auf unsicherer Datenlage. Wer das haltlos nennt, fordert Scheingewissheit. Die wäre wirklich lebensgefährlich.
Wenigstens wird am Beispiel Kerkeling noch einmal deutlich, was sie meinen, wenn sie von Experten oder Sachverständigen sprechen:
Meinung. Ganz viel Meinung. Ahnung braucht es dafür nicht.
"Das war eine Einschätzung meinerseits. Vielen Dank!"
Egal wie daneben das auch alles ist. Am Ende wartet das Bundestverdienstkreuz für so viel für 99,9% schädliche Meinung.
nitter.cf/IndikativJetzt/status/…
Philipp Doc retweeted
A technically good apical four-chamber view should capture the true LV apex.
Foreshortening can make the ventricle appear shorter and more spherical, potentially affecting LV volumes, ejection fraction, and wall motion assessment.
BE Bulwer
#MedTwitter #Echocardiography #Cardiology #CardiacImaging
The numbers are stretched, no question. But I don't think the end is near: with only ~30% of S&P 500 reporting a quantified AI impact, diffusion is still very early. For me the risk is timing, not direction.
Der Spread von 127 bps zwischen Paris und Berlin ist kein Rauschen. Ich frage mich, wie lange die EZB solche Risikoprämien im Euro-Kern noch toleriert. Solche Signale zeigen, dass Investoren Fiskal- und Standortrisiken neu bewerten.
Die globale Zinslandschaft auf einen Blick. Schon krass: Rendite der 10-jährigen Staatsanleihen im September in den USA um 48 Basispunkte gestiegen, in Frankreich sogar um 64 Basispunkte.
Und die Renditedifferenz zwischen Frankreich und Deutschland – den beiden größten Euro-Ländern – liegt nun bei 127 Basispunkten. Da könnte bald wieder die EZB gefordert sein...
Philipp Doc retweeted
📌 evERA trial results✨
Giredestrant plus Everolimus in Advanced Breast Cancer
🔗 nejm.org/doi/full/10.1056/NE…
@OncoAlert #OncoAlertAF @NEJM
@elmayermd @stolaney1 @DFCI_BreastOnc @jhaveri_komal @hoperugo
Phase III | ER+/HER2− advanced #BreastCancer after prior CDK4/6i + ET
👥 373 pts randomized to giredestrant + everolimus vs standard ET + everolimus
🎯 Primary endpoint: PFS
🧬 ESR1-mutated (n=207)
➡️ 10.0 vs 5.5 mo
➡️ HR 0.38 (95% CI 0.27–0.54; P<.001)
👥 Overall population
➡️ 8.8 vs 5.5 mo
➡️ HR 0.56 (95% CI 0.44–0.71; P<.001)
👉 Giredestrant + everolimus significantly improved PFS, with a particularly marked benefit in ESR1-mutated disease.
